Sohm Inc Stock Price, News & Analysis

SOHM, Inc. (OTC PINK:SHMN) has announced a strategic acquisition of a Southern California pharmaceutical company, enhancing its manufacturing capabilities under FDA licensing. This acquisition allows SOHM to operate a cGMP-compliant contract manufacturing facility, previously operational since 2000, which currently produces 41,000 gallons of semi-solid, liquid, and topical products annually. The facility can expand to over 160,000 gallons per year, paving the way for increased revenues and profitability. The company aims to leverage this opportunity for growth in OTC, cosmeceuticals, and veterinary markets.

SOHM, Inc. (OTC PINK:SHMN) has announced a definitive agreement to acquire a leading pharmaceutical company in Southern California. This acquisition aligns with SOHM's strategy for stability and growth, allowing for the establishment of a manufacturing hub in the USA. The phased acquisition will enable SOHM to manufacture US-branded products in-house, enhancing profitability and opening new contract manufacturing opportunities. The company envisions increased revenues and financial stability following the integration.

SOHM, Inc. (OTC PINK:SHMN) announced a new repeat order for its prescription skincare topical products, aligning with its B2B strategy. These orders, generated from a private label customer, will be distributed nationwide to major pharmacy chains like Wal-Mart and CVS, enhancing revenues for 2021. CEO Baron Night expressed optimism for future updates and growth, aiming to meet financial goals and achieve significant market presence. SOHM, focused on generic pharmaceuticals, aims for continuous growth in emerging markets.

SOHM, Inc. (OTC PINK: SHMN) has completed its due diligence for the acquisition of a Southern California pharmaceutical company. CEO Baron Night announced that the final acquisition agreement is expected to be signed by the end of the current quarter. This acquisition will enable SOHM to manufacture its products in-house in the U.S., enhancing profitability and expanding contract manufacturing opportunities. The move aligns with SOHM's growth strategy and aims to boost revenue and operational stability.

SOHM, Inc. (OTC PINK:SHMN) announced on August 4, 2021, that it has received a mandate for the development and manufacturing of two new human prescription topical products. The first product aims to treat hyperpigmentation, while the second is a combination medication for minor pain and discomfort related to hemorrhoids. SOHM anticipates that these products will be available in major pharmacy chains such as CVS and Wal-Mart by late Q3 or early Q4 2021. CEO Baron Night highlighted that this mandate represents an annualized commitment once the products are on the market.

SOHM, Inc. (OTC PINK:SHMN) announced a semi-annual order for prescription skincare topical products worth approximately $500,000. This order, placed by a private label customer, will be distributed to major pharmacy chains including Publix, CVS, and Wal-Mart. The initial mandate included seven SKUs but has evolved into the current order. The CEO expressed optimism about achieving positive revenue in 2021 and potentially exceeding the previous year's figures.

SOHM, Inc. (OTC PINK:SHMN) reported a robust Q1 2021, with a 163% year-over-year revenue growth to $32,235 and a gross profit margin increase to 71%. Profitability improved by 38.85%, totaling $7,413. The company anticipates continued growth in Q2 and into the second half of the year, bolstered by new product mandates and potential acquisitions. Management has paused its share buyback to focus on these acquisitions. SOHM is also expanding into the personal care market and expects tripled revenue without acquisitions, with further increases anticipated with them.

SOHM, Inc. (OTC PINK:SHMN) is advancing its growth strategy by focusing on converting prescription products to over-the-counter (OTC) markets. The company plans to capitalize on the trend where over 80% of American consumers prefer private label products for cost efficiency. This shift is expected to foster strategic partnerships with major retail channels, enhancing profitability. SOHM anticipates finalizing a significant acquisition by mid-2021, aligning with its strategic goals. The company aims to expand its footprint in various healthcare segments while enhancing brand integrity.

SOHM, Inc. (OTC PINK:SHMN) has signed a Letter of Intent to acquire a leading Southern California based pharmaceutical company, aiming to establish a stronger manufacturing base within the USA. This strategic move is expected to enhance SOHM's market presence in the generic prescription and OTC segments. The target company, active for over 20 years, offers more than 300 formulations across various categories. The acquisition, subject to due diligence and financing arrangements, aims to increase SOHM's profitability and innovation across its segments.